We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Novartis has partnered with a consortium of life sciences companies to rapidly develop, produce and deliver vaccines, diagnostics and treatments for Covid-19 coronavirus infection.
Changes in technology and geopolitics, coupled with U.S. tax reform and new financial accounting standards, are colliding like weather systems to create possibly the biggest disruption in accounting and financial reporting for life sciences companies sinc